Developer docs
API playgroundTry for free, no card

Search company profiles

Gene Solutions

Full company profile

uuid0000a9k

Namestring
Gene Solutions
Legal namestring
Công Ty Cổ Phần Giải Pháp Gene
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Gene Solutions is a Vietnamese genetic testing company founded in 2017 and headquartered in Ho Chi Minh City, with 501-1,000 employees and operations across Vietnam, Singapore, Taiwan, Indonesia, Malaysia, Thailand, the Philippines, and the United States. The company has cumulatively performed more than 2.2 million genetic tests across a network of 2,200+ partner hospitals and clinics, positioning itself as the leading NIPT provider in Vietnam while building a parallel oncology screening franchise. Its product portfolio spans non-invasive prenatal testing (triSure NIPT, triSure Procare, triSure Carrier, babySure), gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva), multi-cancer early detection (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, SPOT-MAS 10), precision oncology and MRD monitoring (K-4CARE, K-Track, OncoGS), hereditary cancer screening (oncoSure, oncoSure Plus, MenCare, PinkCare), and rare disease diagnostics (G4500 WGS/WES, Diagsure, CNVSure, Mitochondrial Disease).

The underlying technology stack combines cell-free DNA (cfDNA) liquid biopsy, next-generation sequencing, multi-omics analysis (genomic, transcriptomic, epigenomic), and proprietary AI/ML models trained on the largest Vietnamese genetic database. Two CAP-accredited NGS labs — one in Vietnam and one in Singapore — anchor the operation; a Pangea Laboratory partnership is extending the platform into U.S. CLIA/CAP validation, and an Element Biosciences AVITI24 collaboration upgrades the sequencing backbone. SPOT-MAS 10 received FDA Breakthrough Device Designation in May 2026, validating the platform's clinical performance (78.2% sensitivity, 99.8% specificity on a 12,281-individual real-world cohort).

Gene Solutions operates a hybrid B2B2C and direct-to-consumer model. The B2B2C channel is the dominant revenue driver: hospitals and clinics order tests, samples are processed in CAP labs, and results are returned with 5-7 day NIPT turnaround. A direct-to-consumer channel runs through genesolutions.vn, a customer support hotline, and an online results portal. Pricing is not publicly disclosed; revenue is recognized on a one-time per-test basis. The company has raised $36 million in equity across two Mekong Capital rounds (2021, 2023), secured a $200 million HSBC revolving credit facility in 2024, and is targeting a $100 million pre-IPO round in 2026 ahead of a planned 2027 listing in Hong Kong or Singapore. International expansion is being executed through regional channel partners (BDMS in Thailand, NEWCL in Taiwan, ATC Genomics in Turkey, USK Bioscience in China) and clinical validation collaborations (Pangea in the U.S., Raffles Medical in Singapore).

Short descriptiontext

Gene Solutions is a Vietnamese genetic testing company providing non-invasive prenatal testing, multi-cancer early detection, precision oncology, and hereditary disease diagnostics through a 2,200+ hospital partner network across Southeast Asia, with FDA Breakthrough Designation for its SPOT-MAS 10 test and a planned 2027 Hong Kong/Singapore IPO.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSingapore, Singapore
HQ citystring
Singapore
HQ countrystring
Singapore
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genetic testing services, non-invasive prenatal testing, liquid biopsy diagnostics, multi-cancer early detection, hereditary cancer screening
Industry5 codes
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Molecular Diagnostics and Genetic Testing Services
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model1 record
1Genetic Testing Services
TypeOne Time License
Description

Gene Solutions generates revenue primarily through providing genetic and molecular diagnostic testing services. Revenue streams include prenatal testing (NIPT, carrier screening, newborn screening), cancer screening and early detection (ctDNA-based liquid biopsy), cancer treatment guidance (oncology assays), and genetic disease diagnosis. Tests are ordered through healthcare provider partners and directly by consumers, with results returned within specified turnaround times.

genesolutions.vn
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1No public pricing tiers available
ModelOtherBilling cadencePay-as-you-go
Notes

Test-specific pricing is not publicly disclosed. Customers inquire via hotline or website contact forms. The company offers a post-test financial support program: customers with positive SPOT-MAS Eva or epiHERA results receive up to 2,000,000 VND toward invasive procedures/biopsy costs.

genesolutions.vn
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 23 records shown
1SPOT-MAS
Description

Multi-cancer early detection blood test using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning.

genesolutions.vn
+22 more records
Core offering1 text field

Gene Solutions provides genetic and molecular diagnostic testing services through cell-free DNA (cfDNA) liquid biopsy and next-generation sequencing (NGS) technology, organized across five main categories: (1) gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis; (2) pregnancy care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal screening; (3) cancer early detection and treatment support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA analysis; (4) genetic disease diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease); and (5) hereditary disease screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL). All tests are analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore using proprietary AI algorithms optimized for the Vietnamese population.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • SPOT-MAS multi-cancer test demonstrated 78.2% sensitivity and 99.8% specificity in a real-world cohort of 12,281 individuals (2nd International Hereditary Cancers Congress 2026)
+4 more records
Product overview1 text field

Gene Solutions operates a comprehensive genetic testing ecosystem organized across five main categories: (1) Gynecologic Cancer Screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis and HPV detection; (2) Pregnancy Care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal genetic screening; (3) Cancer Early Detection & Treatment Support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA and multi-omics analysis; (4) Genetic Disease Diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease) for whole genome/exome and targeted analysis; and (5) Genetic Screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL) for hereditary cancer and disease risk. The company's tests are powered by proprietary AI algorithms optimized for the Vietnamese population, analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore.

Product and service24 records
1SPOT-MAS 10
CategoryMulti-cancer early detection
Description

Multi-omic blood test for detecting cancer-associated signals across 10 cancer types in asymptomatic adults aged 40+ using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning. Validated in over 9,000 participants and used in more than 100,000 individuals in real-world settings. Demonstrated 78.2% sensitivity and 99.8% specificity in a 12,281-individual cohort.

2SPOT-MAS Eva
CategoryGynecologic cancer screening
Description

Molecular biology test that simultaneously screens for cervical cancer and endometrial cancer from a single cervical cell sample using DNA methylation analysis (PAX1, JAM3, CDO1, CELF4 genes) combined with HPV 28-genotype detection.

3epiHERA
CategoryGynecologic cancer screening
Description

DNA methylation-based test analyzing CDO1 and CELF4 genes to support early detection and risk stratification of endometrial cancer, designed to reduce unnecessary invasive procedures by up to 90%.

4Cervix360
CategoryGynecologic cancer screening
Description

Comprehensive cervical cancer risk stratification solution combining PAX1 and JAM3 gene methylation analysis with HPV genotyping, designed to reduce unnecessary colposcopies by up to 80%.

5triSure NIPT
CategoryPrenatal genetic screening
Description

Non-Invasive Prenatal Testing (NIPT) for prenatal screening of chromosomal abnormalities using cell-free DNA from maternal blood. Optimized for the Vietnamese population using proprietary algorithms and the largest Vietnamese genetic database, with 5-7 day turnaround.

6triSure Procare
CategoryPrenatal genetic screening
Description

Comprehensive genetic screening for common chromosomal abnormalities during pregnancy, offering more complete coverage than standard NIPT.

7triSure Carrier
CategoryReproductive genetic screening
Description

Preconception genetic screening test to assess carrier status for common hereditary genetic conditions before pregnancy.

8babySure
CategoryNewborn genetic screening
Description

Genetic testing for newborns, screening for hereditary conditions that may affect infant health.

9SPOT-MAS
CategoryCancer early detection
Description

Blood-based cancer screening test using ctDNA (circulating tumor DNA) analysis for early cancer detection and risk assessment.

10SPOT-MAS CRC
CategoryCancer early detection
Description

Colorectal cancer screening test using ctDNA methylation analysis for early detection of colorectal cancer.

11SPOT-MAS Lung
CategoryCancer early detection
Description

Lung cancer screening test using ctDNA analysis for early detection of lung cancer.

12K-4CARE
CategoryPrecision oncology
Description

Precision oncology assay combining genomic and transcriptomic profiling with MRD (Minimal Residual Disease) monitoring capabilities for cancer treatment guidance and recurrence detection.

13K-Track
CategoryPrecision oncology
Description

MRD (Minimal Residual Disease) monitoring test for cancer patients to detect residual tumor cells after treatment.

14OncoGS
CategoryPrecision oncology
Description

Genomic profiling test for targeted cancer therapy selection, analyzing tumor biomarkers to guide treatment decisions.

15G4500
CategoryGenetic disease diagnosis
Description

Whole genome sequencing (WGS) and whole exome sequencing (WES) analysis test providing comprehensive genetic information for diagnosis of genetic diseases.

16Diagsure
CategoryGenetic disease diagnosis
Description

Genetic diagnostic test organized by organ systems to help identify causes of genetic diseases and guide more effective treatment.

17CNVSure
CategoryGenetic disease diagnosis
Description

Chromosomal copy number variation analysis test for detecting abnormalities in chromosome number and structure.

18Bệnh ty thể (Mitochondrial Disease)
CategoryGenetic disease diagnosis
Description

Genetic testing for mitochondrial disorders, analyzing 37 mitochondrial DNA (mtDNA) genes to diagnose mitochondrial diseases.

19oncoSure
CategoryHereditary cancer screening
Description

Hereditary cancer screening test for assessing genetic cancer risk in individuals with family history of cancer.

20oncoSure Plus
CategoryHereditary cancer screening
Description

Comprehensive hereditary cancer screening test covering a broader range of cancer types and genetic markers than oncoSure.

21GenCare Premium
CategoryHereditary disease screening
Description

Comprehensive cancer and genetic disease screening package offering broad coverage for cancer risk and hereditary conditions.

22MenCare
CategoryHereditary cancer screening
Description

Hereditary cancer screening test specifically designed for males, assessing risk for male-specific and common hereditary cancers.

23PinkCare
CategoryHereditary cancer screening
Description

Hereditary cancer screening test specifically designed for females, assessing risk for breast, ovarian, and other female-related hereditary cancers.

24GenLDL
CategoryHereditary disease screening
Description

Genetic test for hereditary high cholesterol (familial hypercholesterolemia) to assess cardiovascular disease risk related to genetic lipid metabolism disorders.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-08
Description

Gene Solutions signed a strategic partnership with this specialized obstetrics and gynecology clinic in Quang Tri province to expand access to precision medicine for local patients.

2My Duc Hospital System (He Thong IVF My Duc)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Gene Solutions and My Duc Hospital System signed a strategic cooperation agreement in June 2026 to expand access to precision medicine for patients, with a focus on prenatal and reproductive genetic testing services.

genesolutions.vn
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-15
Description

BDMS Wellness Clinic, part of Bangkok Dusit Medical Services, formed a large-scale public-private alliance to position Thailand as Asia's premier wellness economy hub. Gene Solutions participates alongside global biotech firms Illumina, Abbott, and Straumann Group, GCC partners, Thai national agencies, and academic institutions. The ecosystem integrates precision diagnostics, genomics, regenerative technology, and preventive medicine with a flagship program 'The Journey Within' combining travel, hospitality, and scientific wellness.

4ATC Genomics
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-03-05
Description

ATC Genomics, a Turkey-based molecular diagnostics provider with over 30 years of experience, serves as Gene Solutions' strategic partner for market entry into Turkey. At the 2nd International Hereditary Cancers Congress 2026, Gene Solutions announced its strategic entry into the Turkish market presenting real-world evidence from a cohort of 12,281 individuals demonstrating strong clinical performance.

thehindu.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-21
Description

Strategic collaboration to validate Gene Solutions' AI-powered liquid biopsy assays (SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay with MRD monitoring) for the U.S. market. Pangea Laboratory conducts analytical and clinical validation at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides SOPs, funding, and technical support from its CAP-accredited labs in Singapore and Vietnam.

6NEWCL
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-12-07
Description

Gene Solutions and NEWCL partnered to establish an advanced NGS laboratory in Taiwan focused on prenatal and oncology genetic testing. The move involves localizing Gene Solutions' testing platforms in Taiwan to expand healthcare access and promote genomic innovation in the region.

biopharmaapac.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Raffles Medical and Gene Solutions are collaborating on a project to identify patients for cancer clinical trials, leveraging Gene Solutions' ctDNA testing capabilities and Raffles Medical's clinical trial infrastructure in Singapore.

8Shenzhen USK Bioscience Co., Ltd.
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Gene Solutions and Shenzhen USK Bioscience Co., Ltd. signed an MOU in June 2025 to establish an ultra-modern NGS laboratory in southern China for advanced cancer diagnostics. The partnership targets the Chinese market for cancer genetic testing services.

globenewswire.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-22
Description

Gene Solutions and Element Biosciences entered a strategic collaboration to enhance next-generation sequencing technologies and genetic testing services globally. The partnership leverages Element's AVITI24 multi-omics platform and Gene Solutions' extensive regional network to advance research and clinical applications in prenatal testing and cancer care.

10Vietnamese Hospital and Clinic Network
Strategic tierCoreTypeOthers
Description

Gene Solutions partners with over 2,200 hospitals and clinics across Vietnam for genetic testing services. Key partners include National Cancer Hospital Hanoi, Tam Duc Heart Hospital, Mekong Maternity Hospital, Children's Hospital 2, Hung Vuong Hospital, University of Medicine and Pharmacy Hospital HCMC, Hue Central Hospital, and Hanoi Maternity Hospital. These institutions serve as both testing sites and referral channels.

genesolutions.vn
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Hong Kong-headquartered genetic and diagnostic testing company offering NIPT, cancer screening, and consumer genetics across Asia. Direct comparable in product mix and Asian go-to-market footprint, though Prenetics is publicly listed on NASDAQ and diversified beyond pure genetic testing.

TypeBroad incumbent
Description

China-based global genomics leader offering NIPT, oncology testing, and NGS services at scale. Comparable as a large, low-cost Asian genomics provider competing across reproductive and oncology testing, with established SEA presence.

TypeDirect peer
Description

U.S.-based genetic testing company with a strong NIPT portfolio (Panorama) and Signatera MRD oncology test. Closely comparable in the combination of reproductive and oncology liquid biopsy testing that defines Gene Solutions' portfolio.

TypeDirect peer
Description

U.S. liquid biopsy leader with multi-cancer screening (Shield) and oncology MRD products. Comparable as a cfDNA-based precision oncology company pursuing FDA validation and large-scale screening, though more mature and U.S.-focused.

TypeRegional player
Description

China-headquartered NGS services provider serving academic, clinical, and pharma customers across Asia and globally. Comparable as an Asian NGS/cfDNA testing peer, though more focused on research services than clinical reproductive and oncology screening.

TypeBroad incumbent
Description

U.S.-listed genetic testing incumbent with hereditary cancer (BRACAnalysis) and oncology profiling products. Comparable as a diversified genetic testing company with strong oncology focus and established clinical channels.

TypeBroad incumbent
Description

Global sequencing platform leader whose technology underpins most NGS-based clinical tests. Indirect competitor as Gene Solutions' tech partner Element Biosciences competes directly with Illumina, and Illumina's GRAIL subsidiary competes in multi-cancer screening.

TypeBroad incumbent
Description

U.S.-based precision oncology genomics provider (Roche subsidiary) offering comprehensive genomic profiling. Comparable in oncology testing depth and the precision medicine positioning of Gene Solutions' K-4CARE and OncoGS products.

TypeEmerging player
Description

Singapore-based molecular diagnostics company with NGS and PCR-based test menus spanning infectious disease, oncology, and reproductive health. Comparable as an Asia-headquartered competitor with overlapping NGS-based clinical diagnostics focus.

TypeOthers
Description

U.S.-based NGS platform company whose AVITI24 sequencing technology is integrated by Gene Solutions through a strategic partnership. Relevant as a technology partner/ecosystem enabler rather than a direct clinical testing competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gene Solutions

Molecular Diagnostics and Genetic Testing Servicesgenesolutions.vn

Gene Solutions is a Vietnamese genetic testing company providing non-invasive prenatal testing, multi-cancer early detection, precision oncology, and hereditary disease diagnostics through a 2,200+ hospital partner network across Southeast Asia, with FDA Breakthrough Designation for its SPOT-MAS 10 test and a planned 2027 Hong Kong/Singapore IPO.

What Gene Solutions does

Gene Solutions is a Vietnamese genetic testing company founded in 2017 and headquartered in Ho Chi Minh City, with 501-1,000 employees and operations across Vietnam, Singapore, Taiwan, Indonesia, Malaysia, Thailand, the Philippines, and the United States. The company has cumulatively performed more than 2.2 million genetic tests across a network of 2,200+ partner hospitals and clinics, positioning itself as the leading NIPT provider in Vietnam while building a parallel oncology screening franchise. Its product portfolio spans non-invasive prenatal testing (triSure NIPT, triSure Procare, triSure Carrier, babySure), gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva), multi-cancer early detection (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, SPOT-MAS 10), precision oncology and MRD monitoring (K-4CARE, K-Track, OncoGS), hereditary cancer screening (oncoSure, oncoSure Plus, MenCare, PinkCare), and rare disease diagnostics (G4500 WGS/WES, Diagsure, CNVSure, Mitochondrial Disease).

The underlying technology stack combines cell-free DNA (cfDNA) liquid biopsy, next-generation sequencing, multi-omics analysis (genomic, transcriptomic, epigenomic), and proprietary AI/ML models trained on the largest Vietnamese genetic database. Two CAP-accredited NGS labs — one in Vietnam and one in Singapore — anchor the operation; a Pangea Laboratory partnership is extending the platform into U.S. CLIA/CAP validation, and an Element Biosciences AVITI24 collaboration upgrades the sequencing backbone. SPOT-MAS 10 received FDA Breakthrough Device Designation in May 2026, validating the platform's clinical performance (78.2% sensitivity, 99.8% specificity on a 12,281-individual real-world cohort).

Gene Solutions operates a hybrid B2B2C and direct-to-consumer model. The B2B2C channel is the dominant revenue driver: hospitals and clinics order tests, samples are processed in CAP labs, and results are returned with 5-7 day NIPT turnaround. A direct-to-consumer channel runs through genesolutions.vn, a customer support hotline, and an online results portal. Pricing is not publicly disclosed; revenue is recognized on a one-time per-test basis. The company has raised $36 million in equity across two Mekong Capital rounds (2021, 2023), secured a $200 million HSBC revolving credit facility in 2024, and is targeting a $100 million pre-IPO round in 2026 ahead of a planned 2027 listing in Hong Kong or Singapore. International expansion is being executed through regional channel partners (BDMS in Thailand, NEWCL in Taiwan, ATC Genomics in Turkey, USK Bioscience in China) and clinical validation collaborations (Pangea in the U.S., Raffles Medical in Singapore).

Gene Solutions firmographics

Firmographics
Name
Gene Solutions
Legal name
Công Ty Cổ Phần Giải Pháp Gene
Website
https://genesolutions.vn
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Gene Solutions is a Vietnamese genetic testing company providing non-invasive prenatal testing, multi-cancer early detection, precision oncology, and hereditary disease diagnostics through a 2,200+ hospital partner network across Southeast Asia, with FDA Breakthrough Designation for its SPOT-MAS 10 test and a planned 2027 Hong Kong/Singapore IPO.
Ownership category
akta.pro rank

Gene Solutions industry classification

Industry
Product category
Molecular Diagnostics and Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAAALAJ
Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine

Keywords

  • Genetic testing services
  • Non-invasive prenatal testing
  • Liquid biopsy diagnostics
  • Multi-cancer early detection
  • Hereditary cancer screening

Where Gene Solutions is headquartered

Location

Headquarters

HQ city
Singapore
HQ country
Singapore
HQ region
Asia

Offices5 records

Markets served

Gene Solutions business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Genetic Testing Services: Gene Solutions generates revenue primarily through providing genetic and molecular diagnostic testing services. Revenue streams include prenatal testing (NIPT, carrier screening, newborn screening), cancer screening and early detection (ctDNA-based liquid biopsy), cancer treatment guidance (oncology assays), and genetic disease diagnosis. Tests are ordered through healthcare provider partners and directly by consumers, with results returned within specified turnaround times.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo public pricing tiers available

Go-to-market motion4 records

Distribution channels6 records

Marketing channels7 records

Gene Solutions product offering

Product offering

Core offering

Gene Solutions provides genetic and molecular diagnostic testing services through cell-free DNA (cfDNA) liquid biopsy and next-generation sequencing (NGS) technology, organized across five main categories: (1) gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis; (2) pregnancy care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal screening; (3) cancer early detection and treatment support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA analysis; (4) genetic disease diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease); and (5) hereditary disease screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL). All tests are analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore using proprietary AI algorithms optimized for the Vietnamese population.

Product overview

Gene Solutions operates a comprehensive genetic testing ecosystem organized across five main categories: (1) Gynecologic Cancer Screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis and HPV detection; (2) Pregnancy Care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal genetic screening; (3) Cancer Early Detection & Treatment Support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA and multi-omics analysis; (4) Genetic Disease Diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease) for whole genome/exome and targeted analysis; and (5) Genetic Screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL) for hereditary cancer and disease risk. The company's tests are powered by proprietary AI algorithms optimized for the Vietnamese population, analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore.

Differentiator

Problem solved

Functional benefit

Brands

  • SPOT-MAS: Multi-cancer early detection blood test using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning.
  • SPOT-MAS 10
  • SPOT-MAS Eva
  • SPOT-MAS CRC
  • SPOT-MAS Lung
  • K-4CARE
  • K-Track
  • OncoGS
  • triSure NIPT
  • triSure Procare
  • triSure Carrier
  • babySure
  • epiHERA
  • Cervix360
  • GenCare Premium
  • oncoSure
  • oncoSure Plus
  • GenLDL
  • MenCare
  • PinkCare
  • G4500
  • Diagsure
  • CNVSure

Products and services

  • SPOT-MAS 10 Multi-omic blood test for detecting cancer-associated signals across 10 cancer types in asymptomatic adults aged 40+ using cell-free DNA methylation and fragmentomic signatures analyzed through machine learning. Validated in over 9,000 participants and used in more than 100,000 individuals in real-world settings. Demonstrated 78.2% sensitivity and 99.8% specificity in a 12,281-individual cohort.
  • SPOT-MAS Eva Molecular biology test that simultaneously screens for cervical cancer and endometrial cancer from a single cervical cell sample using DNA methylation analysis (PAX1, JAM3, CDO1, CELF4 genes) combined with HPV 28-genotype detection.
  • epiHERA DNA methylation-based test analyzing CDO1 and CELF4 genes to support early detection and risk stratification of endometrial cancer, designed to reduce unnecessary invasive procedures by up to 90%.
  • Cervix360 Comprehensive cervical cancer risk stratification solution combining PAX1 and JAM3 gene methylation analysis with HPV genotyping, designed to reduce unnecessary colposcopies by up to 80%.
  • triSure NIPT Non-Invasive Prenatal Testing (NIPT) for prenatal screening of chromosomal abnormalities using cell-free DNA from maternal blood. Optimized for the Vietnamese population using proprietary algorithms and the largest Vietnamese genetic database, with 5-7 day turnaround.
  • triSure Procare Comprehensive genetic screening for common chromosomal abnormalities during pregnancy, offering more complete coverage than standard NIPT.
  • triSure Carrier Preconception genetic screening test to assess carrier status for common hereditary genetic conditions before pregnancy.
  • babySure Genetic testing for newborns, screening for hereditary conditions that may affect infant health.
  • SPOT-MAS Blood-based cancer screening test using ctDNA (circulating tumor DNA) analysis for early cancer detection and risk assessment.
  • SPOT-MAS CRC Colorectal cancer screening test using ctDNA methylation analysis for early detection of colorectal cancer.
  • SPOT-MAS Lung Lung cancer screening test using ctDNA analysis for early detection of lung cancer.
  • K-4CARE Precision oncology assay combining genomic and transcriptomic profiling with MRD (Minimal Residual Disease) monitoring capabilities for cancer treatment guidance and recurrence detection.
  • K-Track MRD (Minimal Residual Disease) monitoring test for cancer patients to detect residual tumor cells after treatment.
  • OncoGS Genomic profiling test for targeted cancer therapy selection, analyzing tumor biomarkers to guide treatment decisions.
  • G4500 Whole genome sequencing (WGS) and whole exome sequencing (WES) analysis test providing comprehensive genetic information for diagnosis of genetic diseases.
  • Diagsure Genetic diagnostic test organized by organ systems to help identify causes of genetic diseases and guide more effective treatment.
  • CNVSure Chromosomal copy number variation analysis test for detecting abnormalities in chromosome number and structure.
  • Bệnh ty thể (Mitochondrial Disease) Genetic testing for mitochondrial disorders, analyzing 37 mitochondrial DNA (mtDNA) genes to diagnose mitochondrial diseases.
  • oncoSure Hereditary cancer screening test for assessing genetic cancer risk in individuals with family history of cancer.
  • oncoSure Plus Comprehensive hereditary cancer screening test covering a broader range of cancer types and genetic markers than oncoSure.
  • GenCare Premium Comprehensive cancer and genetic disease screening package offering broad coverage for cancer risk and hereditary conditions.
  • MenCare Hereditary cancer screening test specifically designed for males, assessing risk for male-specific and common hereditary cancers.
  • PinkCare Hereditary cancer screening test specifically designed for females, assessing risk for breast, ovarian, and other female-related hereditary cancers.
  • GenLDL Genetic test for hereditary high cholesterol (familial hypercholesterolemia) to assess cardiovascular disease risk related to genetic lipid metabolism disorders.

Quantifiable outcome

  • SPOT-MAS multi-cancer test demonstrated 78.2% sensitivity and 99.8% specificity in a real-world cohort of 12,281 individuals (2nd International Hereditary Cancers Congress 2026)
  • +4 more outcomes

Companies that use Gene Solutions

Customer profile

Named customers13 records

Segments5 records

Ideal customer profiles4 records

Gene Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Gene Solutions partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor, strategic, flagship and core.

  • Phong Kham San Phu Khoa Hiem Muon ThS.BSNT Tran Trung HoanhminorStrategic or Co-development Partner · 8 June 2026Gene Solutions signed a strategic partnership with this specialized obstetrics and gynecology clinic in Quang Tri province to expand access to precision medicine for local patients.
  • My Duc Hospital System (He Thong IVF My Duc)strategicStrategic or Co-development Partner · 1 June 2026Gene Solutions and My Duc Hospital System signed a strategic cooperation agreement in June 2026 to expand access to precision medicine for patients, with a focus on prenatal and reproductive genetic testing services.
  • BDMS Wellness Clinic (Bangkok Dusit Medical Services)flagshipStrategic or Co-development Partner · 15 March 2026BDMS Wellness Clinic, part of Bangkok Dusit Medical Services, formed a large-scale public-private alliance to position Thailand as Asia's premier wellness economy hub. Gene Solutions participates alongside global biotech firms Illumina, Abbott, and Straumann Group, GCC partners, Thai national agencies, and academic institutions. The ecosystem integrates precision diagnostics, genomics, regenerative technology, and preventive medicine with a flagship program 'The Journey Within' combining travel, hospitality, and scientific wellness.
  • ATC GenomicsstrategicTechnology or Integration · 5 March 2026ATC Genomics, a Turkey-based molecular diagnostics provider with over 30 years of experience, serves as Gene Solutions' strategic partner for market entry into Turkey. At the 2nd International Hereditary Cancers Congress 2026, Gene Solutions announced its strategic entry into the Turkish market presenting real-world evidence from a cohort of 12,281 individuals demonstrating strong clinical performance.
  • Pangea LaboratorycoreTechnology or Integration · 21 January 2026Strategic collaboration to validate Gene Solutions' AI-powered liquid biopsy assays (SPOT-MAS multi-cancer early detection test and K-4CARE precision oncology assay with MRD monitoring) for the U.S. market. Pangea Laboratory conducts analytical and clinical validation at its CLIA/CAP-accredited facility in Irvine, California, while Gene Solutions provides SOPs, funding, and technical support from its CAP-accredited labs in Singapore and Vietnam.
  • NEWCLstrategicStrategic or Co-development Partner · 7 December 2025Gene Solutions and NEWCL partnered to establish an advanced NGS laboratory in Taiwan focused on prenatal and oncology genetic testing. The move involves localizing Gene Solutions' testing platforms in Taiwan to expand healthcare access and promote genomic innovation in the region.
  • Raffles MedicalminorStrategic or Co-development Partner · 27 October 2025Raffles Medical and Gene Solutions are collaborating on a project to identify patients for cancer clinical trials, leveraging Gene Solutions' ctDNA testing capabilities and Raffles Medical's clinical trial infrastructure in Singapore.
  • Shenzhen USK Bioscience Co., Ltd.strategicStrategic or Co-development Partner · 1 June 2025Gene Solutions and Shenzhen USK Bioscience Co., Ltd. signed an MOU in June 2025 to establish an ultra-modern NGS laboratory in southern China for advanced cancer diagnostics. The partnership targets the Chinese market for cancer genetic testing services.
  • Element BiosciencescoreTechnology or Integration · 22 April 2025Gene Solutions and Element Biosciences entered a strategic collaboration to enhance next-generation sequencing technologies and genetic testing services globally. The partnership leverages Element's AVITI24 multi-omics platform and Gene Solutions' extensive regional network to advance research and clinical applications in prenatal testing and cancer care.
  • Vietnamese Hospital and Clinic NetworkcoreOthersGene Solutions partners with over 2,200 hospitals and clinics across Vietnam for genetic testing services. Key partners include National Cancer Hospital Hanoi, Tam Duc Heart Hospital, Mekong Maternity Hospital, Children's Hospital 2, Hung Vuong Hospital, University of Medicine and Pharmacy Hospital HCMC, Hue Central Hospital, and Hanoi Maternity Hospital. These institutions serve as both testing sites and referral channels.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

Gene Solutions competitors and assessment

Company assessment

Direct peers

  • Prenetics Group: Hong Kong-headquartered genetic and diagnostic testing company offering NIPT, cancer screening, and consumer genetics across Asia. Direct comparable in product mix and Asian go-to-market footprint, though Prenetics is publicly listed on NASDAQ and diversified beyond pure genetic testing.
  • Natera: U.S.-based genetic testing company with a strong NIPT portfolio (Panorama) and Signatera MRD oncology test. Closely comparable in the combination of reproductive and oncology liquid biopsy testing that defines Gene Solutions' portfolio.
  • Guardant Health: U.S. liquid biopsy leader with multi-cancer screening (Shield) and oncology MRD products. Comparable as a cfDNA-based precision oncology company pursuing FDA validation and large-scale screening, though more mature and U.S.-focused.

Broad incumbents

  • BGI Genomics: China-based global genomics leader offering NIPT, oncology testing, and NGS services at scale. Comparable as a large, low-cost Asian genomics provider competing across reproductive and oncology testing, with established SEA presence.
  • Myriad Genetics: U.S.-listed genetic testing incumbent with hereditary cancer (BRACAnalysis) and oncology profiling products. Comparable as a diversified genetic testing company with strong oncology focus and established clinical channels.
  • Illumina: Global sequencing platform leader whose technology underpins most NGS-based clinical tests. Indirect competitor as Gene Solutions' tech partner Element Biosciences competes directly with Illumina, and Illumina's GRAIL subsidiary competes in multi-cancer screening.
  • Foundation Medicine (Roche): U.S.-based precision oncology genomics provider (Roche subsidiary) offering comprehensive genomic profiling. Comparable in oncology testing depth and the precision medicine positioning of Gene Solutions' K-4CARE and OncoGS products.

Regional players

  • Novogene: China-headquartered NGS services provider serving academic, clinical, and pharma customers across Asia and globally. Comparable as an Asian NGS/cfDNA testing peer, though more focused on research services than clinical reproductive and oncology screening.

Emerging players

  • Vela Diagnostics: Singapore-based molecular diagnostics company with NGS and PCR-based test menus spanning infectious disease, oncology, and reproductive health. Comparable as an Asia-headquartered competitor with overlapping NGS-based clinical diagnostics focus.

Others

  • Element Biosciences: U.S.-based NGS platform company whose AVITI24 sequencing technology is integrated by Gene Solutions through a strategic partnership. Relevant as a technology partner/ecosystem enabler rather than a direct clinical testing competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Gene Solutions social profiles

Digital presence

Gene Solutions compliance and trust

Trust signal

Compliance2 records

Gene Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gene Solutions leadership team

Management profile

Number of profiles

Profiles3 records

Gene Solutions subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Gene Solutions funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gene Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gene Solutions

What does Gene Solutions do?

Gene Solutions provides genetic and molecular diagnostic testing services through cell-free DNA (cfDNA) liquid biopsy and next-generation sequencing (NGS) technology, organized across five main categories: (1) gynecologic cancer screening (epiHERA, Cervix360, SPOT-MAS Eva, SPOT-MAS 10) using DNA methylation analysis; (2) pregnancy care (triSure NIPT, triSure Procare, triSure Carrier, babySure) for prenatal and neonatal screening; (3) cancer early detection and treatment support (SPOT-MAS, SPOT-MAS CRC, SPOT-MAS Lung, K-4CARE, K-Track, OncoGS) using ctDNA analysis; (4) genetic disease diagnosis (G4500/WGS/WES, Diagsure, CNVSure, Mitochondrial Disease); and (5) hereditary disease screening (GenCare Premium, oncoSure, oncoSure Plus, MenCare, PinkCare, GenLDL). All tests are analyzed in CAP-accredited NGS laboratories in Vietnam and Singapore using proprietary AI algorithms optimized for the Vietnamese population.

Is Gene Solutions a public or private company?

Gene Solutions is a private company. It is classified as venture growth investor backed and is currently operating.

When was Gene Solutions founded?

Gene Solutions was founded in 2017. It employs 501 to 1,000 people.

Where is Gene Solutions based?

Gene Solutions is headquartered in Singapore, Singapore, in the Asia region.

How does Gene Solutions make money?

One revenue line is on record: genetic Testing Services.

Who are Gene Solutions's main competitors?

Direct peers on record are Prenetics Group, Natera and Guardant Health. Broad incumbents are BGI Genomics, Myriad Genetics, Illumina and Foundation Medicine (Roche). Novogene is listed as a regional player. Vela Diagnostics is listed as an emerging player. Element Biosciences is listed as an others.

Does Gene Solutions have an API?

No public API is recorded for Gene Solutions.

What industry is Gene Solutions in?

Gene Solutions's product category is Molecular Diagnostics and Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The TribuneGene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' AcademyGene Solutions Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 in Kuala Lumpur, bringing together oncology experts from the UAE, Singapore, Malaysia, US, and Vietnam to discuss how tumor DNA and RNA insights can guide more informed treatment decisions. The Academy, an extension of the international K-CONNECT Platform and the recent K-CONNECT Summit 2026 held in Vietnam, featured scientific lectures, case discussions, and workshops focused on multi-omic approaches combining tissue and liquid biopsy testing for cancer molecular profiling. Through the K-CONNECT Platform and Precision Oncology Academy initiatives, Gene Solutions aims to translate scientific advancement in cancer genomics into practical clinical learning for clinicians across the region.The HinduGene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' AcademyGene Solutions Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 in Petaling Jaya, Malaysia, under the theme "Beyond Actionable," bringing together oncology experts from the UAE, Singapore, Malaysia, US, and Vietnam. The Academy featured scientific lectures, case discussions, and workshops focused on translating tumour DNA, RNA, and circulating tumour DNA (ctDNA) insights into confident clinical treatment decisions. The event served as an extension of the international K-CONNECT Platform and followed the K-CONNECT Summit 2026 held in Vietnam.BusinessLineGene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' AcademyGene Solutions Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 in Petaling Jaya, Malaysia, bringing together oncology experts from the UAE, Singapore, Malaysia, US, and Vietnam to discuss advances in precision oncology. The Academy examined multi-omic approaches including K-4CARE, which combines tissue-based DNA and RNA profiling with liquid biopsy circulating tumour DNA analysis, and featured case discussions on how serial molecular profiling can guide treatment decisions for cancers such as ALK-positive lung cancer. The event extended the international K-CONNECT Platform established by Gene Solutions, aiming to translate genomic insights into confident clinical decisions that improve patient care.PR Newswire APACGene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' AcademyGene Solutions Malaysia hosted the Precision Oncology Academy 2026 on July 25, 2026, in Kuala Lumpur, bringing together oncology experts from the UAE, Singapore, Malaysia, US, and Vietnam to discuss advanced genomic profiling and liquid biopsy applications in cancer treatment decisions. The Academy, aligned with the international K-CONNECT Platform established by Gene Solutions, featured scientific lectures and case discussions on multi-omic approaches such as K-4CARE, which combines tissue-based DNA and RNA profiling with circulating tumor DNA analysis for molecular profiling and monitoring. Gene Solutions, a Singapore-headquartered biotechnology company, positioned the event as part of its mission to translate precision oncology advances into practical clinical learning across the region.ANTARA NewsGene Solutions Showcases Global Evidence and Responsible InnovationGene Solutions participated as a Premier Partner at the ISPD 2026 conference, presenting clinical data and research across prenatal screening, AI-enabled pregnancy risk assessment, and endometrial cancer triage. A key presentation reported findings from 225,092 Asian pregnant women screened for 18 recessive conditions through NIPT infrastructure across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan region, and India between February 2025 and February 2026. The company also highlighted AI-driven research on predicting gestational diabetes and preterm birth using fragmentomic signals from existing cell-free DNA data, and validated a methylation-based endometrial cancer triage assay showing 90.2% sensitivity and 96.2% specificity.BusinessLineGene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026Gene Solutions participated as a Premier Partner at ISPD 2026, presenting real-world evidence from a study screening 225,092 Asian pregnant women for 18 recessive conditions across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan, and India, finding that more than one in four women carried at least one screened condition. The company also showcased AI-driven multi-omic biomarkers for predicting gestational diabetes and preterm birth from routine NIPT data, and presented clinical validation data for its epiHERA cervical DNA methylation assay for endometrial cancer triage, achieving 90.2% sensitivity and 96.2% specificity. Gene Solutions operates across more than 20 markets and is expanding globally beyond Asia into Europe, the Middle East, Africa, and Latin America.The HinduGene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026Gene Solutions participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026) from July 7–9, presenting research across an industry symposium, scientific sessions, oral presentations, and scientific posters on genomics, epigenomics, and AI in prenatal and women's health. The company presented large-scale real-world evidence from screening 225,092 Asian pregnant women for 18 common recessive conditions across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan region, and India between February 2025 and February 2026, finding that more than one in four women carried at least one screened condition. Gene Solutions also showcased advances in AI-driven biomarkers for predicting gestational diabetes and preterm birth, and presented data on its epiHERA methylation-based endometrial cancer triage test, while highlighting its continued expansion across Europe, the Middle East, Africa, and Latin America.MacaubusinessGene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women’s Genomic Health at ISPD 2026Gene Solutions participated as Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), presenting real-world evidence from screening 225,092 Asian pregnant women for 18 recessive conditions across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan, and India between February 2025 and February 2026. The company showcased its triSure Procare integrated NIPT and carrier screening platform alongside advances in AI-driven pregnancy risk assessment and the epiHERA methylation assay for endometrial cancer triage, which demonstrated 90.2% sensitivity and 96.2% specificity in US validation cohorts. Gene Solutions announced expanded commercialization efforts across Europe, the Middle East, Africa, and Latin America as part of its continued geographic expansion from its Asia-focused origins.The TribuneGene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026Gene Solutions participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), presenting findings across industry symposia, scientific sessions, and poster presentations. The company shared real-world evidence from a study of 225,092 Asian pregnant women screened for 18 common recessive conditions across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan region, and India between February 2025 and February 2026, as well as clinical validation data for its epiHERA endometrial cancer triage assay. The conference presentations highlighted Gene Solutions' expanding global footprint spanning more than 20 markets and underscored its commitment to responsible innovation in prenatal and women's genomic health.BusinessLineGene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women's Genomic Health at ISPD 2026Gene Solutions participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), presenting real-world evidence from 225,092 Asian pregnant women screened for 18 common recessive conditions across Vietnam, the Philippines, Indonesia, Malaysia, Taiwan region and India between February 2025 and February 2026, finding that more than one in four pregnant women carried at least one screened recessive condition. The company also showcased validation data for epiHERA, a cervical-sample DNA methylation assay for endometrial cancer triage, demonstrating 90.2% sensitivity and 96.2% specificity in validation cohorts, and presented emerging AI-driven multi-omic biomarker research for predicting gestational diabetes and preterm birth from cell-free DNA data.